PL41069B1 - - Google Patents
Download PDFInfo
- Publication number
- PL41069B1 PL41069B1 PL41069A PL4106955A PL41069B1 PL 41069 B1 PL41069 B1 PL 41069B1 PL 41069 A PL41069 A PL 41069A PL 4106955 A PL4106955 A PL 4106955A PL 41069 B1 PL41069 B1 PL 41069B1
- Authority
- PL
- Poland
- Prior art keywords
- bis
- hydroxycoumarin
- chromonyl
- methane
- derivatives
- Prior art date
Links
- 239000000126 substance Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- VXIXUWQIVKSKSA-UHFFFAOYSA-N 4-hydroxycoumarin Chemical class C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IMQJXJOIQBIHAM-UHFFFAOYSA-N 4-hydroxy-3-[[3-(2-oxopropyl)phenyl]methyl]chromen-2-one Chemical compound CC(=O)CC1=CC=CC(CC=2C(OC3=CC=CC=C3C=2O)=O)=C1 IMQJXJOIQBIHAM-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- FBPJRNBLWSMDII-UHFFFAOYSA-N azanium;butan-1-ol;hydroxide Chemical compound [NH4+].[OH-].CCCCO FBPJRNBLWSMDII-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Publications (1)
Publication Number | Publication Date |
---|---|
PL41069B1 true PL41069B1 (cs) | 1958-04-15 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Atkins et al. | Substituted coumarins and azacoumarins. Synthesis and fluorescent properties | |
EP0202589A2 (en) | Pharmaceutical compositions containing ascorbic acid derivatives | |
DE4318550A1 (de) | Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DD141833A5 (de) | Verfahren zur herstellung von o-substituierten derivaten des(+)-cyanidan-3-ols | |
DE2359536C2 (de) | 2,6-Diaminonebularinderivate | |
US4298614A (en) | 5'-Aminoalkyl-4',4-dialkylpsoralens | |
US4269851A (en) | 8-Aminoalkyl-4-alkylpsoralens | |
DE3715779A1 (de) | Flavon-3-carbonsaeure-verbindungen sowie verfahren, zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
EP0095640A1 (de) | Alkylenverbrückte Guanidinothiazolderivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel | |
Seidman et al. | Studies on 4-Hydroxycoumarins. X. Acylation of 3-(α-Phenyl-β-acetylethyl)-4-hydroxycoumarin1 | |
PL41069B1 (cs) | ||
SU1391495A3 (ru) | Способ получени производных 3-фенил-2-пропенамина в виде Z-изомеров или их терапевтически совместимых солей | |
DE3537207A1 (de) | Chalkonderivate | |
DE69326111T2 (de) | Hydantoinderivate, deren Salze und diese enthaltende Maillard-Reaktionsinhibitoren | |
DE2007345A1 (de) | Neue substituierte Hexahydroimidazochinoline und deren Säureanlagerungssalze | |
DE2253914C3 (de) | Chromon-3-acrylsaeuren, verfahren zu ihrer herstellung sowie diese verbindung enthaltende arzneimittel | |
DE2602314A1 (de) | Verfahren zur herstellung eines flavonderivates | |
DE3438244C2 (cs) | ||
Spalding et al. | Heterocyclic Basic Compounds. XIII. 4-Aminocoumarin Derivatives | |
US2789937A (en) | Chromonyl-3-(4-hydroxycoumarinyl-3)-methane | |
Thurston et al. | Asymmetric syntheses. IV. The action of optically active nitrates on 2-bromo-fluorene | |
US3682899A (en) | 1-oxo - 3-benzal-thiochromanone derivatives and a process for the production of these compounds | |
DE3426564A1 (de) | Verwendung von 4h-1,4-benzothiazinen bei der prophylaxe und therapie von erkrankungen der atemwege, entzuendungen/rheuma, thromboembolischen erkrankungen, ischaemien und infarkten, herzrhythmusstoerungen, arteriosklerose und dermatosen, arzneimittel zu diesem zweck sowie wirkstoffe, die in diesen arzneimitteln enthalten sind | |
EP0071150A1 (de) | Sulfimine, deren Salze und deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel | |
DE1695682A1 (de) | Neue heterocyclischer Verbindungen und Verfahren zu deren Herstellung |